MA43066A - Procédés de préparation d'acides biliaires et de leurs dérivés - Google Patents
Procédés de préparation d'acides biliaires et de leurs dérivésInfo
- Publication number
- MA43066A MA43066A MA043066A MA43066A MA43066A MA 43066 A MA43066 A MA 43066A MA 043066 A MA043066 A MA 043066A MA 43066 A MA43066 A MA 43066A MA 43066 A MA43066 A MA 43066A
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- preparation
- methods
- bile acids
- solvate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
- C07J7/0035—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a hydroxy group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
La présente invention concerne un procédé de préparation de composés de formule (i) ou d'un sel, solvate, ou conjugué d'acides aminés pharmaceutiquement acceptable associé, où r
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562198733P | 2015-07-30 | 2015-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43066A true MA43066A (fr) | 2018-06-06 |
Family
ID=57885146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043066A MA43066A (fr) | 2015-07-30 | 2016-07-22 | Procédés de préparation d'acides biliaires et de leurs dérivés |
Country Status (15)
Country | Link |
---|---|
US (1) | US10414791B2 (fr) |
EP (1) | EP3328817A4 (fr) |
JP (1) | JP6830096B2 (fr) |
KR (1) | KR20180030204A (fr) |
CN (1) | CN108025994A (fr) |
AR (1) | AR105555A1 (fr) |
AU (1) | AU2016297821B2 (fr) |
BR (1) | BR112018001869A2 (fr) |
CA (1) | CA2993540A1 (fr) |
IL (1) | IL256971A (fr) |
MA (1) | MA43066A (fr) |
MX (1) | MX2018001145A (fr) |
NZ (1) | NZ739219A (fr) |
TW (1) | TW201710280A (fr) |
WO (1) | WO2017019524A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3305799A3 (fr) * | 2016-10-07 | 2018-06-20 | Lupin Limited | Sels d'acide obéticholique |
EP3613754B1 (fr) | 2017-04-20 | 2023-07-12 | Daewoong Bio Inc. | Procédé de préparation d'un dérivé d'acide biliaire par une réaction à écoulement continu |
CN107200763B (zh) * | 2017-06-01 | 2019-05-03 | 江苏佳尔科药业集团有限公司 | 一种以鹅去氧胆酸为原料合成石胆酸的方法 |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
CN111072744B (zh) * | 2019-12-03 | 2021-09-14 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成熊去氧胆酸的方法 |
WO2022039983A2 (fr) * | 2020-08-21 | 2022-02-24 | Sandhill One, Llc | Procédés de fabrication de dérivés d'acide cholique et leurs matières premières |
CN112220792A (zh) * | 2020-09-30 | 2021-01-15 | 浙江大学 | 石胆酸用于制备缓解肝纤维化的药物中的应用 |
WO2023081658A2 (fr) * | 2021-11-02 | 2023-05-11 | Sandhill One, Llc | Tudca dérivé d'origine non animale de haute pureté |
WO2023081657A2 (fr) * | 2021-11-02 | 2023-05-11 | Sandhill One, Llc | Udca d'origine non-animale de pureté élevée |
CN114276397A (zh) * | 2021-12-28 | 2022-04-05 | 湖北武当安泰药业有限公司 | 醋酸去氢表雄酮的制备方法 |
WO2023187398A1 (fr) | 2022-03-31 | 2023-10-05 | NZP UK Limited | Acide 7-cétolithocholique destiné à être utilisé dans le traitement de la dysbiose intestinale et en tant que prébiotique |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4360470A (en) | 1980-10-22 | 1982-11-23 | Hoffmann-La Roche Inc. | Process and intermediates for the synthesis of Vitamin D3 metabolites and chenodeoxycholic acid |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
EP2083621A4 (fr) | 2006-11-20 | 2010-03-24 | Satori Pharmaceuticals Inc | Modulateurs de la production de bêta-amyloïde |
EP2069383A2 (fr) | 2007-06-19 | 2009-06-17 | Kythera Biopharmaceuticals, Inc. | Composition, procédé et préparation d'acide biliaire synthétique |
US20080318870A1 (en) * | 2007-06-19 | 2008-12-25 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
WO2012047495A2 (fr) * | 2010-09-27 | 2012-04-12 | Kythera Biopharmaceuticals, Inc. | Méthodes de synthèse d'acides biliaires synthétiques et compositions les incluant |
HUE062616T2 (hu) * | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
CN102746356B (zh) * | 2012-07-17 | 2014-03-05 | 湖北芳通药业股份有限公司 | 均相法生产醋酸去氢表雄酮的工艺方法 |
EP3865135A3 (fr) | 2013-03-13 | 2021-11-03 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs destinés à l'utilisation thérapeutique |
CN103145784B (zh) | 2013-03-25 | 2015-03-11 | 浙江仙琚制药股份有限公司 | 醋酸去氢表雄酮的制备方法 |
CN104045676A (zh) * | 2013-12-13 | 2014-09-17 | 成都丽璟科技有限公司 | 一种生产双烯醇酮醋酸酯的方法 |
-
2016
- 2016-07-22 BR BR112018001869A patent/BR112018001869A2/pt active Search and Examination
- 2016-07-22 CA CA2993540A patent/CA2993540A1/fr not_active Abandoned
- 2016-07-22 AU AU2016297821A patent/AU2016297821B2/en not_active Ceased
- 2016-07-22 EP EP16831137.1A patent/EP3328817A4/fr not_active Withdrawn
- 2016-07-22 MX MX2018001145A patent/MX2018001145A/es unknown
- 2016-07-22 WO PCT/US2016/043611 patent/WO2017019524A1/fr active Application Filing
- 2016-07-22 US US15/748,716 patent/US10414791B2/en not_active Expired - Fee Related
- 2016-07-22 JP JP2018504706A patent/JP6830096B2/ja active Active
- 2016-07-22 NZ NZ739219A patent/NZ739219A/en not_active IP Right Cessation
- 2016-07-22 KR KR1020187005202A patent/KR20180030204A/ko unknown
- 2016-07-22 MA MA043066A patent/MA43066A/fr unknown
- 2016-07-22 CN CN201680053880.6A patent/CN108025994A/zh active Pending
- 2016-07-26 TW TW105123574A patent/TW201710280A/zh unknown
- 2016-08-01 AR ARP160102334A patent/AR105555A1/es unknown
-
2018
- 2018-01-17 IL IL256971A patent/IL256971A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201710280A (zh) | 2017-03-16 |
EP3328817A1 (fr) | 2018-06-06 |
KR20180030204A (ko) | 2018-03-21 |
US20190010184A1 (en) | 2019-01-10 |
CA2993540A1 (fr) | 2017-02-02 |
IL256971A (en) | 2018-03-29 |
WO2017019524A1 (fr) | 2017-02-02 |
MX2018001145A (es) | 2018-06-15 |
AR105555A1 (es) | 2017-10-18 |
BR112018001869A2 (pt) | 2018-09-18 |
US10414791B2 (en) | 2019-09-17 |
CN108025994A (zh) | 2018-05-11 |
AU2016297821B2 (en) | 2020-03-12 |
NZ739219A (en) | 2019-03-29 |
JP2018523654A (ja) | 2018-08-23 |
AU2016297821A1 (en) | 2018-02-15 |
EP3328817A4 (fr) | 2019-04-03 |
JP6830096B2 (ja) | 2021-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018001491A (es) | Metodos para la preparacion de acidos biliares y derivados de los mismos. | |
MA43066A (fr) | Procédés de préparation d'acides biliaires et de leurs dérivés | |
PH12018500777A1 (en) | Farnesoid x receptor modulators | |
MX2018005520A (es) | Metodos para preparacion de acido obeticolico y derivados de los mismos. | |
MX361653B (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
EA201592055A1 (ru) | 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов | |
MX2023001876A (es) | Derivados de rapamicina. | |
PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
EA032972B1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
MX2018003649A (es) | Metodos e intermedios para la preparacion de derivados de acido biliar. | |
MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
MX2019006165A (es) | Proceso para la preparacion de derivados del acido biliar de las sulfonilureas. | |
WO2014155300A3 (fr) | Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 | |
IN2013MU02828A (fr) | ||
PH12016501461A1 (en) | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors | |
SA520411635B1 (ar) | A2a مشتق حلقي مدمج كمثبط مستقبل | |
MX2018009503A (es) | Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, metodos de preparacion y usos. | |
WO2015068175A3 (fr) | Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci | |
MX2018012777A (es) | Métodos para preparación de ácido obeticólico y derivados de los mismos. | |
MX2018008799A (es) | Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica. | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
MY191352A (en) | Aldosterone synthase inhibitors | |
IL277066B1 (en) | History of lna-dicarboxylic acid and process for their preparation | |
MX2018015990A (es) | Compuestos terapeuticos. |